ABCL

Abcellera Biologics Inc.

A Vancouver biotech company that hunts for new medicines by mining the immune system's own antibodies. Using microfluidics, single-cell screening and machine learning, it sifts through millions of immune cells to find antibodies that drug partners like Eli Lilly can turn into treatments. Born in 2012 out of University of British Columbia research, its name blends "Ab" (the shorthand for antibody) with "cell." During the pandemic it helped find an antibody from a recovered COVID-19 patient's blood sample that became part of a widely used treatment.

CUSIP: 00288U106HealthcareUS1 holder

Ownership Activity Financials Filings

ABCL

ABCL

Entry into a Material Definitive Agreement

Regulation FD Disclosure

Other Events

Results of Operations and Financial Condition

Other Events

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Other Events

Submission of Matters to a Vote of Security Holders